SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of July 2024
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
July 18, 2024
2
Exhibit 99.1
|
Appendix 3B - Proposed issue of securities |
Announcement Summary
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
18/7/2024
The Proposed issue is:
A placement or other type of issue
Total number of +securities proposed to be issued
for a placement or other type of issue
ASX +security code | |
+Security description | |
Maximum
Number of
+securities
to be issued | |
| |
| |
| | |
ATH | |
ORDINARY FULLY PAID | |
| 75,220,800 | |
Proposed +issue date
18/7/2024
Refer to next page for full details of the announcement
Appendix 3B - Proposed issue of securities | 1/5 |
|
Appendix 3B - Proposed issue of securities |
Part 1 - Entity and announcement details
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any
of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing
Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for
quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the
ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known,
in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and
applying for their quotation).
1.2 Registered Number Type |
|
Registration Number |
|
|
|
ABN |
|
37080699065 |
ATH
New announcement
1.5 | Date of this announcement |
18/7/2024
1.6 | The Proposed issue is: |
A placement or other type of issue
Appendix 3B - Proposed issue of securities | 2/5 |
|
Appendix 3B - Proposed issue of securities |
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals
need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
No
Part 7B - Issue details
Is the proposed security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX)
or an ‘Existing class’ (additional securities in a class that is already quoted or recorded by ASX)? |
|
Will the proposed issue of this +security include an offer of attaching
+securities? |
|
|
|
Existing class |
|
No |
Details of +securities proposed to be issued
Asx +Security Code And Description
ATH : ORDINARY FULLY PAID
Number of +securities proposed to be issued
75,220,800
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
Yes
In what currency is the cash consideration being paid? |
|
What is the issue price per +security? |
|
|
|
AUD - Australian Dollar |
|
AUD 0.00540 |
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
Appendix 3B - Proposed issue of securities | 3/5 |
|
Appendix 3B - Proposed issue of securities |
Part
7C - Timetable
7C.1 Proposed +issue date
18/7/2024
Part
7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security
holder approval for the entire issue under listing rule 7.1?
No
7D.1b Are any of the +securities proposed to be issued
without +security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
No
7D.1c Are any of the +securities proposed to
be issued without +security holder approval using the entity’s additional 10% placement capacity under listing rule 7.1A (if applicable)?
Yes
7D.1c ( i ) How many +securities are proposed to be issued without +security holder
approval using the entity’s additional 10% placement capacity under listing rule 7.1A?
75,220,800
7D.1c ( ii ) Please explain why the entity has
chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security
holders would have been eligible to participate
Due
to the costs and timing benefits of completing the placement.
7D.2 Is a party referred to in listing rule 10.11 participating
in the proposed issue?
No
7D.3 Will any of the +securities to be issued be +restricted
securities for the purposes of the listing rules?
No
7D.4 Will any of the +securities to be issued be subject
to +voluntary escrow?
No
Appendix 3B - Proposed issue of securities | 4/5 |
|
Appendix 3B - Proposed issue of securities |
Part
7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the
proposed issue?
No
7E.2 Is the proposed issue to be underwritten?
No
7E.4 Details of any other material fees or costs to be incurred
by the entity in connection with the proposed issue
Part 7F -
Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
To
further research and development activities and provide on-going working capital.
7F.1 Will the entity be changing its dividend/distribution
policy if the proposed issue proceeds?
No
7F.2 Any other information the entity wishes to provide about the proposed issue
7F.3 Any on-sale of the +securities proposed
to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of
the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5),
708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Appendix 3B - Proposed issue of securities | 5/5 |
Alterity Therapeutics (PK) (USOTC:PRNAF)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024